-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HykGqLvpbzlznfh8y80t6T/zTAT+F7GMqSLGYrTTtTGBqg6NN/qKl3USjkpm97Ul
 fO9R4sWKrwChznbbB4fslg==

<SEC-DOCUMENT>0000950123-11-015571.txt : 20110218
<SEC-HEADER>0000950123-11-015571.hdr.sgml : 20110218
<ACCEPTANCE-DATETIME>20110218132616
ACCESSION NUMBER:		0000950123-11-015571
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110218
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110218
DATE AS OF CHANGE:		20110218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		11623735

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y04568e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#Y04568toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549<BR>
<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>
<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of Earliest Event Reported): February&nbsp;18, 2011</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Protalix BioTherapeutics, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in its charter)</B></DIV>
<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Florida</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>001-33357</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>65-0643773</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(State or other jurisdiction <BR>
of incorporation)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(IRS Employer<BR>
Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>2 Snunit Street</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Science Park, POB 455</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Carmiel, Israel</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20100</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Zip Code)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Registrant&#146;s telephone number, including area code &#043;972-4-988-9488</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(Former name or former address, if changed since last report.)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>











<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<!-- TOC -->
<A name="Y04568toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#Y04568000">Item&nbsp;7.01. Regulation&nbsp;FD Disclosure</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#Y04568001">Item&nbsp;9.01. Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#Y04568002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="y04568exv99w1.htm">EX-99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04568toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;7.01. Regulation&nbsp;FD Disclosure" -->
<DIV align="left"><A NAME="Y04568000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;7.01. Regulation&nbsp;FD Disclosure</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On February&nbsp;18, 2011, Protalix BioTherapeutics, Inc. (the &#147;Company&#148;) issued a press release
announcing that new clinical data from the Company&#146;s switchover trial of taliglucerase alfa in
Gaucher disease patients, the Company&#146;s lead product candidate, and preclinical data on oral enzyme
glucocerebrosidase (oral GCD) will be presented at the 7th Annual Meeting of the Lysosomal Disease
Network: WORLD Symposium 2011 in Las Vegas, Nevada. The presentations are also scheduled to take
place on February&nbsp;18, 2011. A copy of the press release is attached hereto as Exhibit&nbsp;99.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The information contained in Item&nbsp;7.01 of this report and in Exhibit&nbsp;99.1 shall not be deemed
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), or incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing.
</DIV>

<!-- link2 "Item&nbsp;9.01. Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="Y04568001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(d)&nbsp;Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press release dated February&nbsp;18, 2011
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04568toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="Y04568002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: February 18, 2011&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David Aviezer
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David Aviezer, Ph.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President and
Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y04568exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Protalix to Present New Data on taliglucerase alfa and Preclinical Data on Oral Enzyme glucocerebrosidase at the WORLD Lysosomal Disease Network Symposium</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CARMIEL, Israel, February&nbsp;18, 2011/PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX,
TASE:PLX), announced today that new clinical data from the switchover trial of taliglucerase alfa
in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will
be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011
in Las Vegas, Nevada. Both drug candidates are unique in that they are produced through the
Company&#146;s proprietary plant-cell protein expression system.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Switchover Trial of taliglucerase alfa</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Gregory Pastores, M.D., Associate Professor of Neurology and Pediatrics and Director of the
Neurogenetics Laboratory at New York University School of Medicine and a study investigator, will
present new data from the Company&#146;s switchover trial during an oral session titled: &#147;Plant Cell
Expressed Recombinant Glucocerebrosidase taliglucerase alfa as Therapy for Gaucher Disease in
Patients Previously Treated with Imiglucerase.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Interim results from the switchover trial support the safety and maintenance of efficacy of
taliglucerase alfa in patients with Gaucher disease who were previously on imiglucerase,&#148; said Dr.
Gregory Pastores.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The switchover trial is a phase III multicenter, open-label clinical trial designed to assess the
safety and efficacy of taliglucerase alfa in Gaucher disease patients who are currently being
treated with imiglucerase (Cerezyme<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>) enzyme replacement therapy. Patients eligible for
the switchover trial are evaluated for 12&nbsp;weeks to establish the stability of their disease.
Patients with confirmed stable disease are switched from imiglucerase (doses ranging from 10-60
U/kg every other week) to an equivalent dose of taliglucerase alfa using the same number of units
for a nine-month period. Adult enrollment in the study has been completed (n=25); pediatric
enrollment remains open. The trial is being conducted in 10 centers throughout North America,
Europe, Israel and Australia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Pastores
will present clinical trial data from an interim report completed in August&nbsp;2010 which
includes efficacy data from 15 patients and safety data from 25 patients. The data indicate that
patients can safely be switched to taliglucerase alfa from imiglucerase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The efficacy analysis from the interim report (n=15) demonstrates that, on average, hemoglobin and
platelet count, spleen volume and liver volume all remained stable over the nine-month period, and
no patients showed a sustained clinical deterioration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The safety analysis from the interim report (n=25, as performed at the time of data lock)
demonstrates that taliglucerase alfa was well tolerated and no drug related severe adverse events
were reported. No patients experienced hypersensitivity reactions, one patient
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">developed antibodies to taliglucerase alfa and no patients developed neutralizing antibodies. Most
adverse events were considered unrelated to taliglucerase alfa. The most frequent mild to moderate
adverse event was nasopharyngitis, a viral infection of the upper respiratory system.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company and Pfizer Inc. have filed a new drug application (NDA)&nbsp;or a marketing authorization
application (MAA), as applicable, for taliglucerase alfa in the United States, European Union,
Brazil and Israel. The Company received a Prescription Drug User Fee Act (PDUFA)&nbsp;date of February
25, 2011 from the U.S. Food and Drug Administration for the taliglucerase alfa NDA.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Oral Enzyme glucocerebrosidase</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Yoseph Shaaltiel, Ph.D., the Company&#146;s Executive Vice President, Research and Development, will
present preclinical data on the Company&#146;s Oral enzyme glucocerebrosidase (oral GCD) during an oral
session titled: &#147;Oral Delivery of Recombinant Glucocerebrosidase Enzyme Naturally Encapsulated in
Carrot Cells.&#148; Oral GCD is a plant cell expressed form of GCD that is naturally encapsulated
within carrot cells genetically engineered to express the GCD enzyme.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Preclinical studies of oral GCD demonstrate the stability of the enzyme in the cell and the
capacity of the cell&#146;s cellulose wall to protect the enzyme against degradation in the digestive
tract in an <I>in-vitro </I>model of the stomach and intestines. Additionally, rats fed lyophilized
carrot cells expressing GCD have accumulated the active enzyme in the target organs, the spleen and
liver.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oral GCD is being developed for the treatment of Gaucher disease. The Company intends to initiate
phase I clinical trials in carriers of Gaucher disease who show reduced enzymatic activity at
baseline.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Protalix</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Protalix is a biopharmaceutical company focused on the development and commercialization of
recombinant therapeutic proteins expressed through its proprietary plant cell based expression
system, ProCellEx&#153;. Protalix&#146;s unique expression system presents a proprietary method for
developing recombinant proteins in a cost-effective, industrial-scale manner in an environment free
of mammalian components and viruses. Protalix&#146;s lead compound, taliglucerase alfa, an enzyme
replacement therapy for the treatment of Gaucher disease, completed phase III clinical development.
Regulatory applications have been submitted for taliglucerase alfa in the United States, the
European Union, Brazil and Israel. Taliglucerase alfa is available to patients with Gaucher
disease in the United States under an Expanded Access protocol, in Brazil under a supply agreement,
in France under an ATU program, as well as to patients in several member states of the European
Union, Israel and other countries under Named Patient provisions.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Protalix&#146;s development pipeline also includes: PRX-105, a pegylated recombinant human
acetylcholinesterase in development for several therapeutic and prophylactic indications, a
biodefense program and an organophosphate-based pesticide treatment program; PRX-102, a modified
version of the recombinant human alpha-GAL-A protein, for the treatment of Fabry disease; an
orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the
treatment of Gaucher disease; and pr-antiTNF, a biosimilar version of etanercept (Enbrel&#153;), for the
treatment of rheumatoid arthritis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Safe Harbor Statement</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ
materially from the statements made. These statements are based on our current beliefs and
expectations as to such future outcomes. Drug discovery and development involve a high degree of
risk. Factors that might cause material differences include, among others, risks relating to: the
successful preclinical development of our product candidates; the completion of our clinical
trials; the review process of the U.S. Food and Drug Administration (FDA), the European Medicines
Agency (EMEA), other foreign regulatory bodies and other governmental regulatory bodies, including
the risk that regulatory authorities may find that the data from our clinical trials and other
studies is insufficient for regulatory approval; delays in the FDA&#146;s, the EMEA&#146;s or other health
regulatory authorities&#146; approval of any applications we file or refusals to approve such filings,
including the new drug application (NDA)&nbsp;and the marketing authorization applications (MAAs) we
filed with the FDA, the EMEA and other health regulatory authorities for taliglucerase alfa for the
treatment of Gaucher disease; refusals by such regulatory authorities to approve the marketing and
sale of a drug product even after acceptance of an application we file or submit for any such drug
product; the identification of lead compounds; the risk that we may fail to satisfy certain
conditions relating to grants we have received from the Office of the Chief Scientist of Israel&#146;s
Ministry of Industry and Trade which may lead to our being required to refund grants previously
received together with interest and penalties; and other factors described in our filings with the
Securities and Exchange Commission. Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining
promising earlier trial results or in preliminary findings for such clinical trials. Further, even
if favorable testing data is generated from clinical trials of drug products, the FDA, EMEA or any
other foreign regulatory authority may not accept or approve an NDA filed or MAA submitted by a
pharmaceutical or biotechnology company for such drug product. Failure to obtain approval from the
FDA, EMEA or any other foreign regulatory authority of any of our
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">drug candidates in a timely manner, if at all, will severely undermine our business and results of
operations by reducing our potential marketable products and our ability to generate corresponding
product revenues. The statements in this release are valid only as of the date hereof and we
disclaim any obligation to update this information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Investor Contact</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Marcy Nanus<BR>
The Trout Group, LLC<BR>
Telephone: 646-378-2927<BR>
Email: mnanus@troutgroup.com

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
